Trial
NCT01372618
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
NYU Langone Health
Collaborators
—
Condition
Ductal Carcinoma in Situ
Intervention
SOM 230 / Pasireotide
Why stopped
PI has passed away. Requested by department to terminate study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-27